ストックスクリーナーアプリを入手
1.77
4.84%
-0.09
アフターアワーズ：
1.78
0.01
+0.56%
前日終値:
$1.86
開ける：
$1.85
24時間の取引高:
112.94K
Relative Volume:
0.59
時価総額：
$26.21M
収益：
-
当期純損益:
$-26.26M
株価収益率:
-0.2589
EPS:
-6.8353
ネットキャッシュフロー:
$-26.82M
1週間 パフォーマンス:
-0.56%
1か月 パフォーマンス:
-1.12%
6か月 パフォーマンス:
+10.28%
1年 パフォーマンス:
-43.18%
1日の値動き範囲:
$1.77
$1.86
1週間の範囲:
$1.74
$1.945
52週間の値動き範囲:
$1.20
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
名前
Tempest Therapeutics Inc
セクター
電話
415-798-8589
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
1.77 | 27.54M | 0 | -26.26M | -26.82M | -6.8353 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-02-08 | 開始されました | Jefferies | Buy |
Tempest Therapeutics Inc (TPST) 最新ニュース
Tempest Therapeutics Inc. (TPST) Q1 2026 Earnings: Significant EPS Miss with No Revenue; Stock Edges UpInterim Report - Newser
Tempest Therapeutics, Inc. 8-K Filing Details and Entity Information for May 19, 2026 - Minichart
Tempest Therapeutics (TPST) Edges Higher as Biotech Sector Shows Renewed InterestDiamond Pattern - Newser
Tempest Therapeutics announces resignation of three board members By Investing.com - Investing.com Australia
Tempest Therapeutics announces resignation of three board members - Investing.com
Tempest Therapeutics Faces Nasdaq Listing and Governance Risks - TipRanks
Tempest Therapeutics Announces Multiple Board Director Resignations - TipRanks
Tempest Therapeutics receives Nasdaq notice for listing deficiencies - Investing.com UK
Tempest Therapeutics receives Nasdaq notice for listing deficiencies By Investing.com - Investing.com Canada
Nasdaq flags Tempest Therapeutics (NASDAQ: TPST) on equity and board gaps - Stock Titan
[8-K] Tempest Therapeutics, Inc. Reports Material Event - Stock Titan
Tempest Therapeutics (TPST) Stock: Jumps +3.65%, Approaching $1.93 2026-05-20Percent Below MA - Newser
Press Releases about Tempest Therapeutics, Inc.Common Stock - The Chronicle-Journal
Tempest Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Tempest Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tempest Therapeutics (NASDAQ: TPST) Q1 2026 loss widens on CAR-T deal charges and low cash - Stock Titan
Tempest Therapeutics reports Q1 2026 net loss of $27.7M, cash $1.8M - TradingView
Tempest Therapeutics Q1 net loss widens on asset acquisition costs - TradingView
Tempest Therapeutics (TPST) posts $27.7M loss, highlights 100% CAR‑T responses - Stock Titan
Tempest CAR-T trials log 100% response in 15 patients - Stock Titan
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
MSN Money - MSN
TradingKey - TradingKey
Tempest Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Tempest Therapeutics Showcases Strong TPST-2003 CAR-T Data - TipRanks
Tempest presents TPST-2003 interim data: 100% CR in 15 CAR-T‑naïve patients, median PFS 23.1 months - TradingView
Tempest Therapeutics | 8-K: Current report - Moomoo
TPST-2003 delivers 100% CRs in rrMM, Tempest (NASDAQ: TPST) says - Stock Titan
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire
TPST Tempest Therapeutics tops Q4 2025 EPS estimates, shares jump more than 14 percent in today’s trading.Trending Buy Opportunities - Newser
TPST Q1'26 Earnings: revenue estimate is 0 USD - TradingView
After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN
Tempest Therapeutics Inc (TPST) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):